Evolving Treatment in Newly Diagnosed Multiple Myeloma Patients - Episode 5
Looking Ahead and Key Takeaways
Elizabeth O’Donnell, MD, comments on the most significant advancements for frontline therapy in transplant-ineligible patients with newly diagnosed multiple myeloma. She also provides key takeaways from the latest clinical trial data, discussing how she anticipates these findings will impact her day-to-day clinical practice.
Video Player is loading.
- Please comment on the most significant advancements on the horizon for frontline therapy in both transplant-ineligible patients with newly diagnosed multiple myeloma.
- Provide your key takeaways from the latest clinical trial data and how you anticipate these findings will impact your day-to-day clinical practice.
Related Content:
